Altimmune announces presentation of pemvidutide clinical data at upcoming nash-tag conference on january 6, 2024

Gaithersburg, md., jan. 02, 2024 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced an abstract on pemvidutide in subjects with metabolic dysfunction-associated steatotic liver disease1 will be presented at the nash-tag conference, which will be held in park city, ut on january 4-6, 2024. pemvidutide is a novel, investigational, peptide-based glp-1/glucagon dual receptor agonist in development for the treatment of obesity and mash2. details for the presentation are as follows:
ALT Ratings Summary
ALT Quant Ranking